At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCVX Vaxcyte, Inc.
Pre-Mkt 11-05 09:09:31 EST
65.68
+4.87
+8.01%
盘前65.01
-0.67-1.02%
04:00 EST
High65.71Low60.04Vol2.26M
Open62.87D1 Closing60.81Amplitude9.32%
Mkt Cap10.31BTradable Cap9.95BTotal Shares157.00M
T/O144.43MT/O Rate1.49%Tradable Shares151.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Is Vaxcyte (PCVX) Undervalued Following Positive OPUS 1 Phase 3 Data?
Simply Wall St.  ·  15:29
Is Vaxcyte (PCVX) Undervalued Following Positive OPUS 1 Phase 3 Data?
Vaxcyte, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  06:19
Vaxcyte, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Vaxcyte Q3 Loss Smaller than Estimates; Plans VAX-31 Filing in First Half of 2028
Reuters  ·  06:07
Vaxcyte Q3 Loss Smaller than Estimates; Plans VAX-31 Filing in First Half of 2028
Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil Reports Sale of Common Shares Worth $137,024.083
Reuters  ·  06:02
Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil Reports Sale of Common Shares Worth $137,024.083
Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate
Benzinga Earnings  ·  05:30
Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate
Vaxcyte Q3 2026 Net Loss Widens 40% to $297.1 Million
Reuters  ·  05:14
Vaxcyte Q3 2026 Net Loss Widens 40% to $297.1 Million
Vaxcyte Q3 Net Income USD -297.062 Million Vs. IBES Estimate USD -310.7 Million
Reuters  ·  05:06
Vaxcyte Q3 Net Income USD -297.062 Million Vs. IBES Estimate USD -310.7 Million
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
THOMSON REUTERS  ·  05:05
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
Vaxcyte options imply 7.1% move in share price post-earnings
TIPRANKS  ·  11-04 04:05
Vaxcyte options imply 7.1% move in share price post-earnings
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at Idweek 2026
THOMSON REUTERS  ·  10-24
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at Idweek 2026
Movement Alert｜Vaxcyte, Inc. Intraday Rise 5.04% in Regular Trading, target price raised after positive Phase 3 vaccine data
Market Focus  ·  10-20
Movement Alert｜Vaxcyte, Inc. Intraday Rise 5.04% in Regular Trading, target price raised after positive Phase 3 vaccine data
Movement Alert｜Vaxcyte, Inc. Rises 5.82% in Pre-Market Trading, Shares Stabilize After Recent VAX-31 Phase 3 Readout and Target Price Increase
Market Focus  ·  10-15
Movement Alert｜Vaxcyte, Inc. Rises 5.82% in Pre-Market Trading, Shares Stabilize After Recent VAX-31 Phase 3 Readout and Target Price Increase
Movement Alert｜Vaxcyte, Inc. Falls 5.08% in Regular Trading, Shares Pull Back After Vaccine Trial Gains
Market Focus  ·  10-14
Movement Alert｜Vaxcyte, Inc. Falls 5.08% in Regular Trading, Shares Pull Back After Vaccine Trial Gains
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Simply Wall St.  ·  10-13
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Cantor Fitzgerald Sticks to Their Buy Rating for Vaxcyte (PCVX)
TIPRANKS  ·  10-12
Cantor Fitzgerald Sticks to Their Buy Rating for Vaxcyte (PCVX)
Vaxcyte Price Target Announced at $120.00/Share by Cantor Fitzgerald
Dow Jones  ·  10-12
Vaxcyte Price Target Announced at $120.00/Share by Cantor Fitzgerald
Vaxcyte Bolsters Capital Structure with New Offerings
TIPRANKS  ·  10-10
Vaxcyte Bolsters Capital Structure with New Offerings
Vaxcyte: Closing of $1.15 Bln Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
THOMSON REUTERS  ·  10-10
Vaxcyte: Closing of $1.15 Bln Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte Closes USD 650 Million Convertible Senior Notes Offering
Reuters  ·  10-10
Vaxcyte Closes USD 650 Million Convertible Senior Notes Offering
Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes
Dow Jones  ·  10-10
Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes

Introduction

Company Name.
Vaxcyte, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Issue price:
--